Chris Bahl is founder and CEO of AI Proteins. The conversation delves into the challenges faced by platform companies in the biotech sector, highlighting the financial pressures that lead to the cutting of innovative projects. It discusses how investors prioritize immediate monetization of assets over long-term development, often resulting in the abandonment of potentially successful platforms.

Takeaways

It's tough out there in the world today to be a platform company.

The fate of most platforms in biotech is that it's a cool engine.

Investors want to monetize that asset.

Hundreds of millions of dollars are needed to get products across the finish line.

Investors are not interested in products that are 10 years away.

Platforms often become line items that get cut from budgets.

Many great platforms are effectively thrown in the trash.

Successful platforms are often discarded due to financial pressures.

Monetization is key for biotech platforms.

Innovation struggles under financial constraints.